With the upcoming release of Wingspan eTMF 2.0, Wingspan Technology is holding an exclusive preview webinar
With the upcoming release of Wingspan eTMF 2.0, Wingspan Technology is holding an exclusive preview webinar
January 13, 2014; BLUE BELL, PA— Wingspan Technology, Inc. plans to release its Wingspan eTMF overhaul, eTMF 2.0 in Q1 2014. On January 22, 2014, Wingspan will debut its revolutionary eTMF product for the first time for public demonstration.
While many document management system interfaces have remained largely unchanged since the 1990s, Wingspan eTMF 2.0 has been re-designed to provide:
· A user experience modeled on commercial web sites such as Amazon and eBay – dramatically reducing user training time and frustration
· Unprecedented insight into the status and health of ongoing trials
· Simple processes for uploading and checking documents that greatly decrease both the time needed for these processes and the possibility of error
Behind the scenes, Wingspan eTMF 2.0 uses the robust and scalable infrastructure and processes that have a proven track record of supporting users in more than 60 countries worldwide in processing up to 10,000 documents per day. Registration for this demo is currently open; you can register online here.
About Wingspan Technology, Inc.
Wingspan Technology, Inc. is the leading provider of life sciences and eClinical software solutions, including Wingspan eTMF and DocWay, the SharePoint/Documentum integration product suite. Wingspan's talented and knowledgeable engineering and project management teams offer in-depth industry knowledge and experience to companies in life sciences, pharmaceutical, financial services, and other fields.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.